Rehmann Capital Advisory Group’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Rehmann Capital Advisory Group’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-69	Closed	-$14	–	2270
2018 Q3	$14	Hold	69	–	–	﹤0.01%	2127
2018 Q2	$18	Buy	+69	New	+$18	﹤0.01%	2104

Other funds holding IMUC

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Rehmann Capital Advisory Group's IMUC Position: Q4 2018 in Review

Rehmann Capital Advisory Group sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 69 shares — an estimated $14 sold.

Rehmann Capital Advisory Group first reported a position in IMUC in Q2 2018 and held it in 2 quarters. The position peaked at $18 in Q2 2018. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.

Rehmann Capital Advisory Group reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
Rehmann Capital Advisory Group sold 69 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018, an estimated $14.
Rehmann Capital Advisory Group first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2018 and held it in 2 quarters.
Rehmann Capital Advisory Group's ImmunoCellular Therapeutics, Ltd. position peaked at $18 in Q2 2018.
3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.

Based on Rehmann Capital Advisory Group's 13F filing for Q4 2018, filed 12 Feb 2019.